Board Chair providing independent governance oversight and strategic accountability for an early-stage medical device company developing a coral-derived bone graft substitute. Leading board cadence, agenda, and decision-making frameworks in a regulated development-stage environment. - Provide independent challenge and oversight to the executive team on strategic direction, capital deployment, and commercialisation priorities. - Establish and lead board governance cadence, KPI frameworks, and accountability structures appropriate to a regulated, pre-commercial medical device business. - Oversee fundraising strategy and support investor engagement, ensuring governance standards meet investor expectations throughout the capital raise process.

Served as President and COO of a regulated medical device startup, working in close strategic partnership with the Board of Directors and investor group throughout the company's growth, capital raises, and strategic restructuring. Responsible for providing the Board with structured performance reporting, risk oversight, and commercial accountability. - Partnered with the Board and investor group across three successive capital raises totalling €10M+, developing the investor narrative, governance materials, and commercial evidence base that sustained board confidence and funding continuity. - Provided the Board with structured performance reporting integrating financial and non-financial metrics, risk management updates, and progress against strategic and operational targets. - Built the company's governance infrastructure from the ground up: KPI frameworks, reporting cadence, stage-gate review processes, and accountability structures. - Led the ISO 13485 quality management system through certification, surveillance, and recertification as a trained internal auditor, ensuring adherence to FDA and EU MDR requirements. - Led recapitalisation planning and strategic restructuring alongside the Board, providing scenario models and decision frameworks for ownership-level decision-making. - Grew enterprise valuation from €8.5M to over €20M within twelve months through disciplined governance of the commercial strategy. - Advisory roles: Industry Advisor at Silverwood Partners and Informal Advisor to Amotio.

Nine years at Stryker Corporation, a global medtech leader operating across 75+ countries, developing deep sector expertise across the Trauma and Extremities and Foot and Ankle businesses. Built comprehensive understanding of large-scale corporate governance, regulated product development, and commercial strategy within a complex, matrixed international organisation. - Managed a $17M+ Foot and Ankle product portfolio, developing deep expertise in medtech commercial strategy, market dynamics, regulatory requirements, and product lifecycle governance. - Developed clinical evidence strategies, KOL engagement programmes, and market positioning for global product launches. - Named inventor on multiple granted patents in shoulder arthroplasty and robotic-assisted orthopaedic technologies. - Programme-managed the ReUnion S shoulder system, coordinating a 40+ person global cross-functional team and delivering in 22 months against a 27-month plan. - Built and scaled a product development function in Cork from scratch to 15+ headcount with full governance accountability. - Contributed to multi-million-dollar acquisition due diligence, evaluating operational readiness, governance maturity, regulatory compliance, and integration risk.